ストックスクリーナーアプリを入手
45.45
16.49%
6.07
前日終値:
$39.38
開ける：
$39.71
24時間の取引高:
108.52K
Relative Volume:
0.67
時価総額：
$3.46B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-18.81%
1か月 パフォーマンス:
-16.30%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$37.50
$46.50
1週間の範囲:
$37.50
$60.58
52週間の値動き範囲:
$9.95
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
MENS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
45.50 | 2.99B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
403.21 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.84 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.38 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
768.65 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
343.93 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Jyong Biotech Ltd (MENS) 最新ニュース
Jyong Biotech (NASDAQ:MENS) Shares Down 8%What's Next? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Shares Gap DownTime to Sell? - MarketBeat
Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards - GlobeNewswire
First Taiwan-Developed Botanical Drug in FDA Phase III: Jyong Biotech Wins Gold for BPH Treatment - Stock Titan
Jyong Biotech (NASDAQ:MENS) Trading Down 6.1%Here's Why - MarketBeat
MENS Stock Price and Chart — NASDAQ:MENS - TradingView
Jyong Biotech (NASDAQ:MENS) Reaches New 52-Week HighStill a Buy? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Shares Gap UpHere's Why - MarketBeat
Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei - GlobeNewswire
Taiwan Biotech Leader Joins Global Business Forum: Jyong CEO to Discuss Cross-Border Innovation - Stock Titan
Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.7%Should You Sell? - MarketBeat
Jyong Biotech completes patient enrollment in Phase II trial of MCS-8 - TipRanks
Jyong Biotech Announces Completion of Patient Enrollment of - GlobeNewswire
Jyong Biotech (NASDAQ:MENS) Sets New 12-Month HighHere's Why - MarketBeat
Enrollment goal met in trial of MCS-8 for prostate cancer prevention - Urology Times
Jyong Biotech completes phase II enrollment of 700+ patients for MCS-8 in prostate cancer prevention trial - MarketScreener
Jyong Biotech (MENS) Wraps Up Phase II Enrollment for Cancer Drug Study - GuruFocus
Jyong Biotech Completes Enrollment in Phase 2 Trial of Prostate Cancer Investigational Drug - MarketScreener
700+ Patient Milestone: Jyong Biotech's Prostate Cancer Prevention Drug Advances in Phase II Trial - Stock Titan
Jyong Biotech (NASDAQ:MENS) Trading Up 9.1%What's Next? - MarketBeat
Evaluating Jyong Biotech (NasdaqGM:MENS): What Recent Price Moves Reveal About Its Current Valuation - Yahoo Finance
Examining Jyong Biotech (NasdaqGM:MENS) Valuation Following Recent Share Price Momentum - simplywall.st
Shared decision-making: Clarifying roles in prostate cancer care - Urology Times
Biopharma IPO activity slows, but 2025 returns are surging - BioWorld MedTech
Jyong Biotech (NASDAQ:MENS) Sets New 52-Week HighStill a Buy? - MarketBeat
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 - The Motley Fool
Jyong Biotech shares rise 1.06% premarket after being included in a stock market index. - AInvest
Experts discuss the transformative potential of AI for BPH - Urology Times
Jennifer Robles, MD, on future advancements in HoLEP - Urology Times
Jyong Biotech to present clinical data from studies of BOTRESO, MCS-8 - MSN
Jyong Biotech (NASDAQ:MENS) Stock Price Down 6.7%What's Next? - MarketBeat
Jyong Biotech shares rise 1.83% after-hours after participating in the 22nd Urological Association of Asia Congress. - AInvest
Jyong Biotech shares fall 1.93% after-hours following participation in the 22nd Urological Association of Asia Congress. - AInvest
Jyong Biotech Ltd. Participated in the 22nd Urological - GlobeNewswire
Breakthrough: Taiwan's First FDA Phase 3 Botanical Drug BOTRESO Shows Promise in $9.8B BPH Market - Stock Titan
Positive data on BOTRESO and MCS-8 highlight dual advances in prostate health - Urology Times
Jyong Biotech (NASDAQ:MENS) Shares Up 10.5%Here's What Happened - MarketBeat
Biopharma IPO drought continues: chance of rain expected? - BioWorld MedTech
Jennifer Robles, MD, on the impact of regional disparities in HoLEP access - Urology Times
Jyong Biotech Ltd (MENS) 財務データ
Jyong Biotech Ltd (MENS) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.62%
大文字化:
|
ボリューム (24 時間):